Cargando…
Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073661/ https://www.ncbi.nlm.nih.gov/pubmed/33919536 http://dx.doi.org/10.3390/healthcare9040481 |
_version_ | 1783684181270724608 |
---|---|
author | Wehl, Götz Franke, Jörg Frühwirth, Martin Edlinger, Michael Rauchenzauner, Markus |
author_facet | Wehl, Götz Franke, Jörg Frühwirth, Martin Edlinger, Michael Rauchenzauner, Markus |
author_sort | Wehl, Götz |
collection | PubMed |
description | Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-infectious hyperinflammation leading to short-term myocardial injury with yet unknown long-term outcome. We herein present three cases of PIMS-TS treated in our institution with divided doses of immunoglobulins and high dose acetyl salicylic acid, according to existing Kawasaki disease guidelines. Due to greater weight in adolescents affected and concerns of rheological sequelae following possible hyperviscosity, doses of immunoglobulins were divided and given 24 h apart with good tolerability. All patients recovered rapidly with normalization of previously encountered cardiac manifestations. As diagnosis of PIMS-TS should be made promptly, timing of therapy is of paramount importance for a favorable outcome. To date, no randomized controlled trial data exist concerning treatment recommendations. 1.8% (95% CI: 1.7% to 2.0%) of all children and adolescents in the county district of Ostallgäu were tested positive for SARS CoV-2, incidence of PIMS-TS was 1.7% (95% CI: 0.9% to 3.1%) among SARS CoV-2 positive tested earlier. As the pandemic is still ongoing, rising numbers of PIMS-TS in children might be expected. |
format | Online Article Text |
id | pubmed-8073661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80736612021-04-27 Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany Wehl, Götz Franke, Jörg Frühwirth, Martin Edlinger, Michael Rauchenzauner, Markus Healthcare (Basel) Case Report Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-infectious hyperinflammation leading to short-term myocardial injury with yet unknown long-term outcome. We herein present three cases of PIMS-TS treated in our institution with divided doses of immunoglobulins and high dose acetyl salicylic acid, according to existing Kawasaki disease guidelines. Due to greater weight in adolescents affected and concerns of rheological sequelae following possible hyperviscosity, doses of immunoglobulins were divided and given 24 h apart with good tolerability. All patients recovered rapidly with normalization of previously encountered cardiac manifestations. As diagnosis of PIMS-TS should be made promptly, timing of therapy is of paramount importance for a favorable outcome. To date, no randomized controlled trial data exist concerning treatment recommendations. 1.8% (95% CI: 1.7% to 2.0%) of all children and adolescents in the county district of Ostallgäu were tested positive for SARS CoV-2, incidence of PIMS-TS was 1.7% (95% CI: 0.9% to 3.1%) among SARS CoV-2 positive tested earlier. As the pandemic is still ongoing, rising numbers of PIMS-TS in children might be expected. MDPI 2021-04-18 /pmc/articles/PMC8073661/ /pubmed/33919536 http://dx.doi.org/10.3390/healthcare9040481 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Wehl, Götz Franke, Jörg Frühwirth, Martin Edlinger, Michael Rauchenzauner, Markus Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title | Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title_full | Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title_fullStr | Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title_full_unstemmed | Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title_short | Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany |
title_sort | successful treatment of pediatric inflammatory multisystem syndrome temporally associated with covid-19 (pims-ts) with split doses of immunoglobulin g and estimation of pims-ts incidence in a county district in southern germany |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073661/ https://www.ncbi.nlm.nih.gov/pubmed/33919536 http://dx.doi.org/10.3390/healthcare9040481 |
work_keys_str_mv | AT wehlgotz successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany AT frankejorg successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany AT fruhwirthmartin successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany AT edlingermichael successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany AT rauchenzaunermarkus successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany |